¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç° À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Global Multiplex Assay Market, By Product, By Type, By Technology, By Application, By End User, By Geography
»óǰÄÚµå : 1424470
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,354,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,884,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,120,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð´Â 2024³â 16¾ï 9,000¸¸ ´Þ·¯¿¡¼­ 2031³â¿¡´Â 44¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 14.6%ÀÔ´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2023 2023/2024³â ½ÃÀå ±Ô¸ð 16¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031
¿¹Ãø ±â°£2023/2024-2030/2031 CAGR : 14.60% 2030/2031³â °¡Ä¡ ¿¹Ãø 44¾ï ´Þ·¯
µµÇ¥ 1. ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
Global Multiplex Assay Market-IMG1

¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀº ¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡·Î ÀÎÇØ ÃÖ±Ù ¼ö³â°£ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º´Â ÇÑ ¹øÀÇ ºÐ¼®À¸·Î ¿©·¯ ºÐ¼®¹°À» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖÀ¸¸ç, Áø´Ü Á¤È®µµ¿Í 󸮷®À» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ °Ë»ç½ÇÀº ¿î¿µ ºñ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 °Ë»ç ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ¹× ºñµå ±â¹Ý ±â¼úÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀº ÀÓ»ó Áø´Ü ¹× ¿¬±¸¿ë °í°¨µµ, °íƯÀ̼º, °í󸮷® ´ÙÁßÈ­ Ç÷§ÆûÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇâÈÄ ³ëÈ­ °ü·Ã Áúº´¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, Áø´Ü °Ë»ç¿¡ ´ëÇÑ ÀÇ·áºñ ÁöÃâ Áõ°¡, Á¤¹ÐÀÇ·áÀÇ È®´ë´Â ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå ±â¾÷¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇÁ·ÎÅ׿À¹Í½º ¹× À¯ÀüüÇÐ ºÐ¾ßÀÇ È°¹ßÇÑ R&D Ȱµ¿, ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ ¹× ÀÓ»ó Áø´Ü¿¡ ´ëÇÑ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌÀÇ Àû¿ë È®´ë µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ºÐ¼®¹ý °³¹ßÀÇ º¹À⼺°ú ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀÌµå ¹× µðÁöÅÐ PCR ±â¼úÀÇ Ã¤ÅÃÀº ³ôÀº 󸮷®, ³·Àº »ùÇ÷®, ÈÞ´ë¿ë ¸ÖƼÇ÷º½º Ç÷§ÆûÀÇ °³¹ßÀ» ÃËÁøÇÏ¿© »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·°ú ³ôÀº Àåºñ ºñ¿ëµµ ¾î´À Á¤µµ ½ÃÀå È®´ë¿¡ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ±â¼úÀÇ Ã¤Åà Ȯ´ë°¡ ½ÃÀå ¼ºÀåÀÇ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ´Â ÇÑ ¹øÀÇ ½ÇÇèÀ¸·Î ¿©·¯ Ÿ±êÀ» µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ±âÁ¸ÀÇ ½Ì±ÛÇ÷º½º ºÐ¼®¿¡ ºñÇØ ¸¹Àº ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ´Â ÇÑ ¹ø¿¡ ¿©·¯ ºÐ¼® ´ë»óÀ» °Ë»çÇÒ ¼ö ÀÖÀ¸¹Ç·Î ½Ã°£°ú ³ë·ÂÀ» Àý¾àÇÒ ¼ö ÀÖ´Â µî ¿©·¯ Ãø¸é¿¡¼­ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. Å×½ºÆ®¸¦ ÅëÇÕÇÔÀ¸·Î½á ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ´Â ½Ã¾à, ¼Ò¸ðǰ ¹× ½ÇÇè½Ç ¿À¹öÇìµå¿Í °ü·ÃµÈ Àü¹ÝÀûÀÎ ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ´Â °í󸮷® ½ºÅ©¸®´×¿¡ ÀÌ»óÀûÀÌ¸ç ´ë±Ô¸ð ¿¬±¸ ¹× ÀÓ»ó Áø´Ü¿¡ À¯¿ëÇÕ´Ï´Ù. ¸ÖƼÇ÷º½º´Â Á¦ÇÑµÈ ¾çÀÇ »ùÇÃÀ» ºÐ¼®ÇÒ ¼ö ÀÖÀ¸¸ç, »ý°Ë Àç·á³ª Èñ±ÍÇÑ ¼¼Æ÷ Áý´Ü°ú °°Àº ±ÍÁßÇÑ »ùÇÃÀ» º¸Á¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¸é 2021³â 6¿ù, ½Äǰ, ȯ°æ, ÀǾàǰ, È­Àåǰ °Ë»çÀÇ ¼¼°è ¸®´õÀÎ Eurofins´Â SARS-CoV-2 º¯Á¾ÀÇ ½Å¼ÓÇÑ °ËÃâÀ» À§ÇØ °³¹ßµÈ GSD NovaType III SARS-CoV-2 RT-PCR ºÐ¼®¹ý Ãâ½Ã¸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ ºÐ¼®Àº ÇÑ ¹øÀÇ ¹ÝÀÀÀ¸·Î °ü·Ã º¯Á¾ E484Q, E484K, L452RÀ» ½Äº°ÇÏ°í µ¿½Ã¿¡ S À¯ÀüÀÚ E484 ¾ß»ýÇü º¯Á¾°ú ½±°Ô ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¬±¸ÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå, Á¦Ç°º°, 2019-2031³â

Á¦6Àå ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå, À¯Çüº°, 2019-2031³â

Á¦7Àå ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå, ±â¼úº°, 2019-2031³â

Á¦8Àå ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå, ¿ëµµº°, 2019-2031³â

Á¦9Àå ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2031³â

Á¦10Àå ¼¼°èÀÇ ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå, Áö¿ªº°, 2019-2031³â

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¼½¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global multiplex assay market size is expected to reach US$ 4.40 Bn by 2031, from US$ 1.69 Bn in 2024, at a CAGR of 14.6% during the forecast period.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 1.69 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024-2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 14.60% 2030/2031 Value Projection: US$ 4.40 Bn
Figure 1. Global Multiplex Assay Market Share (%), by Region, 2024
Global Multiplex Assay Market - IMG1

The multiplex assay market has been witnessing significant growth in the recent past on account of the rising incidence of chronic and infectious diseases globally. Multiplexing permits simultaneous detection of multiple analytes in a single assay run, which enhances diagnostic accuracy and throughput. It allows laboratories to streamline testing processes while minimizing operational costs. Various technological advancements including microarrays and bead-based techniques have facilitated the development of high-throughput multiplex platforms with high sensitivity and specificity for clinical diagnostics and research applications. Going forward, the growing geriatric population vulnerable to age-related illnesses, increasing healthcare expenditures on diagnostic testing, and expansion of precision medicine are expected to present lucrative opportunities for players in the multiplex assay market.

Market Dynamics:

The multiplex assay market is driven by factors such as growing demand for personalized medicine, robust R&D activity in the field of proteomics and genomics, and increasing applications of multiplex assays in biomarker research and clinical diagnostics. However, complexity of assay development and stringent regulatory framework are some challenges restraining the market growth. Adoption of microfluidics and digital PCR technologies create new opportunities by facilitating development of high-throughput, low sample volume, and portable multiplex platforms. Lack of skilled experts and high cost of instruments also challenge market expansion to some extent.

The growing adoption of multiplex assay techniques is a significant driver for the market. Multiplex assays offer numerous advantages over traditional singleplex assays by allowing the simultaneous analysis of multiple targets in a single experiment, which can drive the market growth in several ways such as multiplex assays can test for multiple analytes at once, saving time and labor compared to running. By consolidating tests, multiplex assays can reduce overall costs associated with reagents and consumables, as well as laboratory overhead. They are ideal for high-throughput screening, making them valuable in large-scale studies and clinical diagnostics. Multiplexing enables analysis from limited sample volumes, preserving precious samples like biopsy material or rare populations of cells.

For instance, in June 2021, Eurofins, the global leader in food, environment, pharmaceutical, and cosmetic product testing, announced the launch of GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 variants. The assay facilitates the identification of the relevant mutations E484Q, E484K, and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant.

Key Features of the Study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Impact of Coronavirus (COVID-19) Pandemic

5. Global Multiplex Assay Market, By Product, 2019-2031, (US$ Bn)

6. Global Multiplex Assay Market, By Type, 2019-2031, (US$ Bn)

7. Global Multiplex Assay Market, By Technology, 2019-2031, (US$ Bn)

8. Global Multiplex Assay Market, By Application, 2019-2031, (US$ Bn)

9. Global Multiplex Assay Market, By End User, 2019-2031, (US$ Bn)

10. Global Multiplex Assay Market, By Region, 2019-2031, (US$ Bn)

11. Competitive Landscape

12. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â